TRPV2 and central nervous system cancer: In agreement with these findings, pharmacological inhibition of the ERK pathway by using PD98059, a specific MEK inhibitor, reverts the TRPV2-mediated effects and stimulates glioma cell survival and proliferation in the U87MG GBM cell line [70].